EGFR and lung carcinoma: miRNA-23a has been shown to inhibit the effectiveness of lung cancer drugs such as EGFR-targeted tyrosine kinase inhibitors by suppressing their ability to phosphorylate PI3K and AKT in lung CSCs, thereby preventing the induction of apoptosis in the cells (Han et al., 2017).